Cibus 過去の業績

過去基準チェック /06

Cibusの収益は年間平均-56.1%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間19.1% 29.4%割合で減少しています。

主要情報

-56.1%

収益成長率

31.9%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	-29.4%
株主資本利益率	-441.9%
ネット・マージン	-10,724.8%
前回の決算情報	30 Sep 2024

Recent updates

Calyxt signs agreement with Evologic to scale production of plant-based ingredients

Oct 07

Calyxt exploring strategic alternatives

Sep 22

Calyxt Switches Gears Again, But The Cash Clock Keeps Ticking Down

Apr 01

Calyxt Needs To Secure More Commercial Partners As Cash Dwindles

Sep 16

収支内訳

Cibus の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:CBUS 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
30 Sep 24	4	-445	25	47
30 Jun 24	3	-292	26	51
31 Mar 24	2	-286	22	44
31 Dec 23	2	-268	16	36
30 Sep 23	1	-53	17	29
30 Jun 23	0	-33	11	15
31 Mar 23	0	-17	10	10
31 Dec 22	0	-17	11	12
30 Sep 22	2	-21	14	12
30 Jun 22	10	-22	14	12
31 Mar 22	22	-25	14	11
31 Dec 21	26	-29	15	11
30 Sep 21	38	-36	16	12
30 Jun 21	35	-38	17	11
31 Mar 21	26	-44	19	11
31 Dec 20	24	-45	21	11
30 Sep 20	14	-44	23	11
30 Jun 20	11	-45	25	12
31 Mar 20	10	-43	26	12
31 Dec 19	7	-40	25	12
30 Sep 19	4	-36	25	11
30 Jun 19	1	-33	23	11
31 Mar 19	0	-31	20	12
31 Dec 18	0	-28	18	10
30 Sep 18	0	-26	16	10
30 Jun 18	0	-32	19	13
31 Mar 18	0	-28	16	11
31 Dec 17	1	-26	15	12
30 Sep 17	0	-24	13	11
30 Jun 17	0	-13	8	6
31 Mar 17	0	-12	7	6
31 Dec 16	0	-12	7	6
31 Dec 15	1	-6	4	3

質の高い収益: CBUSは現在利益が出ていません。

利益率の向上: CBUSは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: CBUSは利益が出ておらず、過去 5 年間で損失は年間56.1%の割合で増加しています。

成長の加速: CBUSの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: CBUSは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。

株主資本利益率

高いROE: CBUSは現在利益が出ていないため、自己資本利益率 ( -441.85% ) はマイナスです。

Cibus 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. Announces Impairment Charges for the Third Quarter Ended September 30, 2024

Cibus, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Full year 2023 earnings released: US$25.95 loss per share (vs US$18.36 loss in FY 2022)

Recent updates

Cibus Achieves Additional Milestone for Next Generation Gene Edits for Sclerotinia Resistance in Canola

Consensus revenue estimates increase by 71%, EPS downgraded

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. Announces Impairment Charges for the Third Quarter Ended September 30, 2024

Cibus, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cibus, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

New major risk - Share price stability

Cibus, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

Cibus, Inc. Announces CFO Changes, Effective September 30, 2024

Consensus EPS estimates fall by 12%

Price target decreased by 10% to US$19.75

New major risk - Financial position

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Cibus, Inc. Expands Its Intellectual Property Coverage for Plant Gene Editing and Traits

New minor risk - Share price stability

Cibus’ White Mold (Sclerotinia) Resistance Trait Program Confirms Important Milestone for Next Generation Gene Edits in Canola

Full year 2023 earnings released: US$25.95 loss per share (vs US$18.36 loss in FY 2022)

Consensus revenue estimates increase by 18%

Cibus, Inc. Appoints Jason Stokes as Chief Legal Officer, General Counsel and Corporate Secretary

Cibus, Inc. to Report Q1, 2024 Results on May 09, 2024

Cibus, Inc., Annual General Meeting, May 30, 2024

Consensus EPS estimates upgraded to US$3.03 loss, revenue downgraded

Consensus EPS estimates fall by 21%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Cibus 2023 Field Trial Results Move Developed Traits Closer to Product Sales

Cibus: Expanding Opportunities And Growing Accessible Market

Cibus, Inc. Announces Successfully Regenerated Plants from Single Cells in Wheat

Cibus, Inc. has filed a Follow-on Equity Offering in the amount of $80 million.

Co-Founder recently bought US$5.5m worth of stock

Cibus, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates increase by 15%, EPS downgraded

Price target decreased by 13% to US$22.00

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Cibus, Inc. Announces Resignation of Jim Collins as Member of Board of Directors and Member of Nominating and Corporate Governance Committee

Is Cibus, Inc. (NASDAQ:CBUS) Trading At A 44% Discount?

Cibus, Inc. Appoints Jim Collins to Board of Directors

Does Cibus (NASDAQ:CBUS) Have A Healthy Balance Sheet?

Consensus revenue estimates fall by 60%

Second quarter 2023 earnings released: US$3.05 loss per share (vs US$2.66 loss in 2Q 2022)

Cibus, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Price target decreased by 50% to US$18.00

Consensus revenue estimates increase by 46%

New major risk - Shareholder dilution

First quarter 2023 earnings released: US$1.09 loss per share (vs US$1.34 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Calyxt, Inc. Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm Oil

Calyxt Gets 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

High number of new directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.20 loss in 3Q 2021)

Calyxt, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Calyxt, Inc Produces Plant-Based Squalene, an Important Ingredient in Personal Care Products and Critical Vaccine Adjuvants

Calyxt signs agreement with Evologic to scale production of plant-based ingredients

Calyxt exploring strategic alternatives

Consensus forecasts updated

Forecast to breakeven in 2024

Second quarter 2022 earnings released: US$0.053 loss per share (vs US$0.13 loss in 2Q 2021)

Price target increased to US$6.83

Calyxt, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Calyxt Receives Non-Compliance Notice from Nasdaq

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$4.99

High number of new directors

Calyxt, Inc. Announces Directorate Appointments

Calyxt, Inc. to Report Q1, 2022 Results on May 05, 2022

過去基準チェック /06